Rossi E D, Martini M, Capodimonti S, Cenci T, Bilotta M, Pierconti F, Pontecorvi A, Lombardi C P, Fadda G, Larocca L M
Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario "Agostino Gemelli" School of Medicine, Rome, Italy.
Division of Endocrinology, Fondazione Policlinico Universitario "Agostino Gemelli" School of Medicine, Rome, Italy.
Cytopathology. 2018 Oct;29(5):418-427. doi: 10.1111/cyt.12555. Epub 2018 May 30.
Several authors have underlined the limits of morphological analysis mostly in the diagnosis of follicular neoplasms (FN). The application of ancillary techniques, including immunocytochemistry (ICC) and molecular testing, contributes to a better definition of the risk of malignancy (ROM) and management of FN. According to literature, the application of models, including the evaluation of ICC, somatic mutations (ie, BRAF ), micro RNA analysis is proposed for FNs. This study discusses the validation of a diagnostic algorithm in FN with a special focus on the role of morphology then followed by ancillary techniques.
From June 2014 to January 2016, we enrolled 37 FNs with histological follow-up. In the same reference period, 20 benign nodules and 20 positive for malignancy were selected as control. ICC, BRAF mutation and miR-375 were carried out on LBC.
The 37 FNs included 14 atypia of undetermined significance/follicular lesion of undetermined significance and 23 FN. Specifically, atypia of undetermined significance/follicular lesion of undetermined significance resulted in three goitres, 10 follicular adenomas and one NIFTP whereas FN/suspicious for FN by seven follicular adenomas and 16 malignancies (nine non-invasive follicular thyroid neoplasms with papillary-like nuclear features, two invasive follicular variant of papillary thyroid carcinoma [PTC] and five PTC). The 20 positive for malignancy samples included two invasive follicular variant of PTC, 16 PTCs and two medullary carcinomas. The morphological features of BRAF mutation (nuclear features of PTC and moderate/abundant eosinophilic cytoplasms) were associated with 100% ROM. In the wild type cases, ROM was 83.3% in presence of a concordant positive ICC panel whilst significantly lower (10.5%) in a negative concordant ICC. High expression values of MirR-375 provided 100% ROM.
The adoption of an algorithm might represent the best choice for the correct diagnosis of FNs. The morphological detection of BRAF represents the first step for the identification of malignant FNs. A significant reduction of unnecessary thyroidectomies is the goal of this application.
多位作者强调了形态学分析在诊断滤泡性肿瘤(FN)方面的局限性。辅助技术的应用,包括免疫细胞化学(ICC)和分子检测,有助于更好地界定恶性风险(ROM)以及对FN的管理。根据文献,对于FN,建议应用包括ICC评估、体细胞突变(即BRAF)、微小RNA分析在内的模型。本研究讨论了FN诊断算法的验证,特别关注形态学的作用,随后是辅助技术。
2014年6月至2016年1月,我们纳入了37例有组织学随访的FN。在同一参考期内,选择20例良性结节和20例恶性阳性病例作为对照。对液基薄层制片(LBC)进行ICC、BRAF突变和miR-375检测。
37例FN包括14例意义未明的非典型性/意义未明的滤泡性病变和23例FN。具体而言,意义未明的非典型性/意义未明的滤泡性病变导致3例甲状腺肿、10例滤泡性腺瘤和1例具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP),而FN/可疑FN由7例滤泡性腺瘤和16例恶性肿瘤组成(9例具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤、2例甲状腺乳头状癌[PTC]的侵袭性滤泡变体和5例PTC)。20例恶性阳性样本包括2例PTC的侵袭性滤泡变体、16例PTC和2例髓样癌。BRAF突变的形态学特征(PTC的核特征和中等/丰富的嗜酸性细胞质)与100%的ROM相关。在野生型病例中,一致阳性ICC组的ROM为83.3%,而在一致阴性ICC组中显著较低(10.5%)。MirR-375的高表达值提供了100%的ROM。
采用一种算法可能是正确诊断FN的最佳选择。BRAF的形态学检测是识别恶性FN的第一步。减少不必要的甲状腺切除术是该应用的目标。